NL-OMON34821尚未招募2 期
A double-blind, randomized, placebo-controlled, two-centre, phase IIa pharmacodynamic cross-over study to assess the effect of AZD2516 on the total number of reflux episodes in healthy male volunteers - PoP study AZD2516
Astra Zeneca0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Provision of informed consent prior to any study specific procedures
- •2. Healthy male subjects, age 18-45 years, inclusive
- •3.Clinically normal physical findings and laboratory values as judged by the investigator.
- •4.Body Mass Index (BMI<=weight/height2) 19-30 kg/m2 calculated from height and weight given in the demographic data.
排除标准
- •1. Clinically significant illness within the 2 weeks prior to the first dose of the investigational product, including a suspected/manifested infection according to WHO risk categories 2, 3 or 4, as judged by the investigator
- •2. Basal LES pressure of < 5 mmHg
- •3. History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, as assessed by using the MINI psychiatric interview.
- •4. Suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale in the last month
- •5. History of psychotic disorder among first-degree relatives
- •6. History of use of antipsychotic, antidepressant or anxiolytic drugs, prescribed as well as non-prescribed use. History of antidepressants or anxiolytics for non-psychiatric conditions such as pain or postoperative insomnia is allowed
- •7. History of clinically significant cardiovascular, respiratory, renal, hepatic, neurological, mental or gastrointestinal disease, as judged by the investigator
- •8. Use of prescribed medication and over-the-counter drugs (including herbal remedies minerals and vitamins) during 2 weeks before administration of investigational product. However, paracetamol may be taken occasionally for pain relief as well as OTC adrenergic nasal spray for relief of nasal congestion
- •9. Administration of any investigational product within 8 weeks prior to the first dose of AZD2516
- •10. Any condition that could modify the absorption of the drug, as judged by the investigator
- •11. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity
- •12. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG obtained at the pre-entry visit, that may interfere with the interpretation of QTc interval changes. This includes subjects with any of the following: Clinically significant PR (PQ) interval prolongation, Intermittent second or third degree AV block, Incomplete, full or intermittent bundle branch block (QRS<120 msec with normal QRS and T wave morphology is acceptable if there is no evidence of left ventricular hypertrophy), Abnormal T wave morphology, particularly in the protocol defined primary lead (lead V2), Prolonged QTcF >450 msec or shortened QTcF <350 msec or family history of long QT syndrome
- •13. Need for concomitant medications during the study (with the exception of OTC nasal spray for relief of nasal congestion and occasional paracetamol for pain relief)
- •14. Habitual smoker (ie, the subjects smokes every day) or daily use of other nicotine products
- •15. Blood donation, or similar blood loss, within 12 weeks prior to the first dose of the investigational product
- •16. Plasma donation within 2 weeks prior to enrolment
- •17. Positive drug of abuse screen or history of drug addiction and/or alcohol abuse or other circumstances which in the investigators judgment may compromise the subject*s ability to comply with the study requirements
- •18. Use of anabolic steroids within 12 months prior to the first dose of investigational product
- •19. Excessive use of caffeine (more than 5 cups of coffee or equivalent per day).
- •20. Involvement in the planning and conduct of the study
- •21. Previous randomization or treatment in the present study or previous exposure to AZD2516.
研究者
相似试验
进行中（未招募）
不适用
A double-blind, randomized, placebo-controlled, two-centre, phase IIa pharmacodynamic cross-over study to assess the effect of AZD2516 on the total number of reflux episodes in healthy male volunteersGastroesophageal Reflux Disease (GERD)MedDRA version: 12.1Level: LLTClassification code 10017924Term: Gastroesophageal refluxEUCTR2010-018608-98-BEAstraZeneca AB40
进行中（未招募）
不适用
Study with random distribution of treatments (fasitibant and placebo given in combination with sodium hyaluronate), where neither the investigator nor the patients know the treatment taken, to evaluate efficacy of the drug when injected into the knee joint in the patients with osteoarthritis of the knee.EUCTR2014-004435-40-CZMenarini Ricerche Spa140
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, two way cross-over study to assess the particle deposition and acute effects of formoterol and budesonide combination therapy (Symbicort® forte Turbohaler®) on the upper airway dimensions in COPD patients.EUCTR2009-016502-16-BEniversity Hospital Antwerp : Department Respiratory Medicine
进行中（未招募）
1 期
To evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of Alzheimer’s diseaseMedDRA version: 18.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Alzheimer's diseaseEUCTR2015-002715-15-NLovartis Pharma Services AG477
进行中（未招募）
1 期
Plerixafor in acute respiratory distress syndrome related to covid-19 (Phase IIb)MedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsSevere COVID-19MedDRA version: 23.1Level: PTClassification code 10084380Term: COVID-19 pneumoniaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2021-001245-13-FR4Living Biotech SAS150